NNC0519-0130: Clinical Trials

10 trials of NNC0519-0130, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 1 recruiting. 7 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7
Phase 23Completed 2, Recruiting 1

Follow NNC0519-0130: new trials by email Literature Review of NNC0519-0130 trials Research Report on NNC0519-0130

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight
NNC0519-0130, Placebo - Diabetes Mellitus, Type 2, Obesity
Phase 1CompletedNovo Nordisk A/S202025-05-262026-03-31
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NNC0519-0130, Placebo, Semaglutide - Chronic Kidney Disease
Phase 2RecruitingNovo Nordisk A/S4652024-12-022026-03-11
A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity
NNC0519-0130 - Obesity
Phase 1CompletedNovo Nordisk A/S1342024-11-202026-04-03
A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes
NNC0519-0130, Placebo - Diabetes Mellitus, Type 2, Obesity
Phase 1CompletedNovo Nordisk A/S822024-08-072025-12-31
A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
NNC0519-0130, Levonorgestrel + Ethinylestradiol, Paracetamol - Diabetes Mellitus, Type 2
Phase 1CompletedNovo Nordisk A/S472024-07-182026-03-12
A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function
NNC0519-0130 - Diabetes Mellitus, Type 2
Phase 1CompletedNovo Nordisk A/S362024-04-152026-04-07
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
NNC0519-0130, Placebo, Tirzepatide - Obesity
Phase 2CompletedNovo Nordisk A/S3542024-03-182026-04-15
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NNC0519-0130, Placebo, Trizepatide - Diabetes Mellitus, Type 2
Phase 2CompletedNovo Nordisk A/S2992024-03-182026-09-21
A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men
NNC0519-0130, Placebo - Diabetes Mellitus, Type 2
Phase 1CompletedNovo Nordisk A/S222023-05-152025-06-18
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
NNC0519-0130, Placebo (NNC0519-0130) - Healthy Volunteers (Diabetes Mellitus, Type 2)
Phase 1CompletedNovo Nordisk A/S1612022-04-202025-12-31

Conditions studied

Diabetes Mellitus, Type 2 (6)  ·  Obesity (4)  ·  Diabetes Mellitus (1)  ·  Renal Insufficiency, Chronic (1)

Sponsors

Novo Nordisk A/S (10)

Countries

Germany (4)  ·  Japan (4)  ·  Australia (3)  ·  United States (3)  ·  India (2)  ·  South Korea (2)  ·  Argentina (1)  ·  Austria (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Italy (1)

NIH funding

2023 (3)